Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels.

Heaney JLJ, Richter A, Bowcock S, Pratt G, Child JA, Jackson G, Morgan G, Turesson I, Drayson MT.

Haematologica. 2019 Aug 8. pii: haematol.2019.224360. doi: 10.3324/haematol.2019.224360. [Epub ahead of print]

2.

Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden.

Ali M, Lemonakis K, Wihlborg AK, Veskovski L, Turesson I, Mellqvist UH, Gullberg U, Hansson M, Nilsson B.

Blood Cancer J. 2019 Jul 30;9(8):57. doi: 10.1038/s41408-019-0222-8. No abstract available.

3.

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1568. [Epub ahead of print]

PMID:
31318385
4.

Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Sverrisdóttir IS, Lund SH, Turesson I, Björkholm M, Goldin LR, Landgren O, Kristinsson SY.

Br J Haematol. 2019 Jul;186(1):37-44. doi: 10.1111/bjh.15883. Epub 2019 Mar 24.

PMID:
30906990
5.

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2019 Jan 10;10(1):213. doi: 10.1038/s41467-018-08107-8.

6.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P.

Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.

7.

UV-Radiation Response Proteins Reveal Undifferentiated Cutaneous Interfollicular Melanocytes with Hyperradiosensitivity to Differentiation at 0.05 Gy Radiotherapy Dose Fractions.

Fessé P, Qvarnström F, Nyman J, Hermansson I, Ahlgren J, Turesson I.

Radiat Res. 2019 Jan;191(1):93-106. doi: 10.1667/RR15078.1. Epub 2018 Nov 8.

PMID:
30407899
8.

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS; PRACTICAL consortium.

Nat Commun. 2018 Sep 13;9(1):3707. doi: 10.1038/s41467-018-04989-w. Erratum in: Nat Commun. 2019 Jan 10;10(1):213.

9.

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes.

Westhrin M, Moen SH, Kristensen IB, Buene G, Mylin AK, Turesson I, Abildgaard N, Waage A, Standal T.

Biomark Res. 2018 Jun 14;6:21. doi: 10.1186/s40364-018-0134-y. eCollection 2018.

10.

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.

Ali M, Ajore R, Wihlborg AK, Niroula A, Swaminathan B, Johnsson E, Stephens OW, Morgan G, Meissner T, Turesson I, Goldschmidt H, Mellqvist UH, Gullberg U, Hansson M, Hemminki K, Nahi H, Waage A, Weinhold N, Nilsson B.

Nat Commun. 2018 Apr 25;9(1):1649. doi: 10.1038/s41467-018-04082-2.

11.

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival.

Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O.

Eur J Haematol. 2018 Apr 20. doi: 10.1111/ejh.13083. [Epub ahead of print] Review.

PMID:
29676004
12.

Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.

Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, Björkholm M, Kristinsson SY.

Haematologica. 2018 Sep;103(9):e412-e415. doi: 10.3324/haematol.2017.183475. Epub 2018 Mar 22. No abstract available.

13.

Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer.

Åström L, Grusell E, Sandin F, Turesson I, Holmberg L.

Radiother Oncol. 2018 Apr;127(1):81-87. doi: 10.1016/j.radonc.2017.12.025.

PMID:
29496280
14.

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Hultcrantz M, Porwit A, Jethava YS, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 22;1(25):2392-2398. doi: 10.1182/bloodadvances.2017007930. eCollection 2017 Nov 28.

15.

Direct evidence for a polygenic etiology in familial multiple myeloma.

Halvarsson BM, Wihlborg AK, Ali M, Lemonakis K, Johnsson E, Niroula A, Cibulskis C, Weinhold N, Försti A, Alici E, Langer C, Pfreundschuh M, Goldschmidt H, Mellqvist UH, Turesson I, Waage A, Hemminki K, Golub T, Nahi H, Gullberg U, Hansson M, Nilsson B.

Blood Adv. 2017 Apr 7;1(10):619-623. doi: 10.1182/bloodadvances.2016003111. eCollection 2017 Apr 11.

16.

Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.

Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY; Swedish Myeloma Registry.

Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7.

17.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
18.

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.

Nahi H, Genell A, Wålinder G, Uttervall K, Juliusson G, Karin F, Hansson M, Svensson R, Linder O, Carlson K, Björkstrand B, Kristinsson SY, Mellqvist UH, Blimark C, Turesson I.

Eur J Haematol. 2017 Sep;99(3):216-222. doi: 10.1111/ejh.12907. Epub 2017 Jun 28.

PMID:
28544116
19.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2018 Apr 1;29(4):1074. doi: 10.1093/annonc/mdx160. No abstract available.

PMID:
28541409
20.

Accelerated or conventional whole brain irradiation of malignant melanoma.

Hultborn R, Sand J, Kinhult S, Lundgren L, Stierner U, Turesson I, Albertsson P.

Acta Oncol. 2017 Jul;56(7):1021-1023. doi: 10.1080/0284186X.2016.1275777. Epub 2017 Jan 11. No abstract available.

PMID:
28075181
21.

Double strand break induction and kinetics indicate preserved hypersensitivity in keratinocytes to subtherapeutic doses for 7weeks of radiotherapy.

Qvarnström F, Simonsson M, Nyman J, Hermansson I, Book M, Johansson KA, Turesson I.

Radiother Oncol. 2017 Jan;122(1):163-169. doi: 10.1016/j.radonc.2016.12.004. Epub 2016 Dec 22.

PMID:
28017476
22.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606. Review. Erratum in: Ann Oncol. 2017 May 24;:.

23.

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Lindqvist EK, Landgren O, Lund SH, Turesson I, Hultcrantz M, Goldin L, Björkholm M, Kristinsson SY.

Ann Hematol. 2017 Feb;96(2):261-269. doi: 10.1007/s00277-016-2859-8. Epub 2016 Nov 2.

24.

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.

Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2016 Jul 1;7:12050. doi: 10.1038/ncomms12050.

25.

Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends.

Vélez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J.

BMJ Open. 2016 Jan 21;6(1):e009584. doi: 10.1136/bmjopen-2015-009584.

26.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG.

Leukemia. 2016 May;30(5):1005-17. doi: 10.1038/leu.2015.356. Epub 2015 Dec 29. Review.

PMID:
26710887
27.

Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.

Jonsdottir G, Lund SH, Björkholm M, Turesson I, Wahlin A, Mailankody S, Blimark C, Hultcrantz M, Porwit A, Landgren O, Kristinsson SY.

Haematologica. 2016 Apr;101(4):e145-8. doi: 10.3324/haematol.2015.134049. Epub 2015 Dec 17. No abstract available.

28.

Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.

Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T.

Haematologica. 2015 Dec;100(12):e511-4. doi: 10.3324/haematol.2015.124511. Epub 2015 Aug 20. No abstract available.

29.

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, Björkholm M, Landgren O, Kristinsson SY.

JAMA Oncol. 2015 May;1(2):168-74. doi: 10.1001/jamaoncol.2015.23.

PMID:
26181017
30.

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.

Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, Waage A, Sundan A, Holien T.

Cell Commun Signal. 2015 Jun 6;13:27. doi: 10.1186/s12964-015-0104-z.

31.

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.

Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, Sulem P, Halvarsson BM, Eyjolfsson G, Haraldsdottir V, Hultman C, Ingelsson E, Kristinsson SY, Kähler AK, Lenhoff S, Masson G, Mellqvist UH, Månsson R, Nelander S, Olafsson I, Sigurðardottir O, Steingrimsdóttir H, Vangsted A, Vogel U, Waage A, Nahi H, Gudbjartsson DF, Rafnar T, Turesson I, Gullberg U, Stefánsson K, Hansson M, Thorsteinsdóttir U, Nilsson B.

Nat Commun. 2015 May 26;6:7213. doi: 10.1038/ncomms8213.

32.

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.

Beksac M, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A.

Acta Haematol. 2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24.

33.

Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival.

Steingrímsson V, Lund SH, Turesson I, Goldin LR, Björkholm M, Landgren O, Kristinsson SY.

Blood. 2015 Mar 26;125(13):2174-5. doi: 10.1182/blood-2015-01-622068. No abstract available.

34.

Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.

Mylin AK, Abildgaard N, Johansen JS, Heickendorff L, Kreiner S, Waage A, Turesson I, Gimsing P; Nordic Myeloma Study Group.

Leuk Lymphoma. 2015;56(9):2650-9. doi: 10.3109/10428194.2015.1004168. Epub 2015 Feb 11.

PMID:
25573204
35.

Effects of a dietary intervention on gastrointestinal symptoms after prostate cancer radiotherapy: long-term results from a randomized controlled trial.

Pettersson A, Nygren P, Persson C, Berglund A, Turesson I, Johansson B.

Radiother Oncol. 2014 Nov;113(2):240-7. doi: 10.1016/j.radonc.2014.11.025. Epub 2014 Nov 29.

PMID:
25467005
36.

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.

Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY.

Haematologica. 2015 Jan;100(1):107-13. doi: 10.3324/haematol.2014.107714. Epub 2014 Oct 24.

37.

Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Hultcrantz M, Pfeiffer RM, Björkholm M, Goldin LR, Turesson I, Schulman S, Landgren O, Kristinsson SY.

J Thromb Haemost. 2014 Nov;12(11):1816-21. doi: 10.1111/jth.12724. Epub 2014 Oct 6.

38.

Cell senescence in myxoid/round cell liposarcoma.

Kåbjörn Gustafsson C, Ståhlberg A, Engtröm K, Danielsson A, Turesson I, Aman P.

Sarcoma. 2014;2014:208786. doi: 10.1155/2014/208786. Epub 2014 Jun 24.

39.

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T.

Blood Cancer J. 2014 Mar 21;4:e196. doi: 10.1038/bcj.2014.16.

40.

Robust isolation of malignant plasma cells in multiple myeloma.

Frigyesi I, Adolfsson J, Ali M, Christophersen MK, Johnsson E, Turesson I, Gullberg U, Hansson M, Nilsson B.

Blood. 2014 Feb 27;123(9):1336-40. doi: 10.1182/blood-2013-09-529800. Epub 2014 Jan 2.

41.

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF.

Leukemia. 2014 Mar;28(3):525-42. doi: 10.1038/leu.2013.350. Epub 2013 Nov 20. Review.

42.

Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.

Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, Landgren O.

Blood. 2014 Jan 16;123(3):338-45. doi: 10.1182/blood-2013-05-505487. Epub 2013 Nov 12.

43.

Assessing patients' perceived bother from the gastrointestinal side effects of radiotherapy for localized prostate cancer: initial questionnaire development and validation.

Pettersson A, Turesson I, Persson C, Johansson B.

Acta Oncol. 2014 Mar;53(3):368-77. doi: 10.3109/0284186X.2013.819994. Epub 2013 Aug 19.

PMID:
23957649
44.

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD.

J Clin Oncol. 2013 Jun 20;31(18):2347-57. doi: 10.1200/JCO.2012.47.7901. Epub 2013 May 20.

45.

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group.

Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24.

46.

Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.

Kristinsson SY, Eloranta S, Dickman PW, Andersson TM, Turesson I, Landgren O, Björkholm M.

Am J Hematol. 2013 Jan;88(1):60-5. doi: 10.1002/ajh.23351. Epub 2012 Nov 19.

47.

Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.

Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H.

AJR Am J Roentgenol. 2012 Nov;199(5):1114-20. doi: 10.2214/AJR.11.8351.

PMID:
23096187
48.

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.

Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P.

Haematologica. 2013 Jan;98(1):87-94. doi: 10.3324/haematol.2012.067058. Epub 2012 Aug 8.

49.

Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer.

Johansson S, Aström L, Sandin F, Isacsson U, Montelius A, Turesson I.

Prostate Cancer. 2012;2012:654861. doi: 10.1155/2012/654861. Epub 2012 Jul 8.

50.

Effects of a dietary intervention on acute gastrointestinal side effects and other aspects of health-related quality of life: a randomized controlled trial in prostate cancer patients undergoing radiotherapy.

Pettersson A, Johansson B, Persson C, Berglund A, Turesson I.

Radiother Oncol. 2012 Jun;103(3):333-40. doi: 10.1016/j.radonc.2012.04.006. Epub 2012 May 24.

PMID:
22633817

Supplemental Content

Loading ...
Support Center